-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Adjuvant chemotherapy can improve the treatment effect of patients with early breast cancer , but the nausea and vomiting (CINV) caused by chemotherapy has brought unbearable pain to patients.
Breast cancer
The study included 120 patients planned for (new) adjuvant treatment of doxorubicin/cyclophosphamide.
The results showed that in the first cycle of doxorubicin/cyclophosphamide, the "complete response" rate of the olanzapine group was significantly higher than that of the standard group: 65.
In summary, the results of this study show that adding olanzapine to a standard antiemetic regimen based on apregabalin can better improve CINV.
Original source:
ncbi.
ncbi.
nlm.
nih.
gov/?term=Yeo+W&cauthor_id=31978815">Yeo Winnie ncbi.
nlm.
nih.
gov/?term=Lau+TK&cauthor_id=31978815">Thomas Lau Kh ncbi.
nlm.
nih.
gov/31978815/" target="_blank" rel="noopener">A randomized Study of the olanzapine-containing versus at The Standard antiemetic regimens for Prevention of Chemotherapy-induced Nausea and vomiting in Chinese Breast Cancer patients in this message